γδ T Cell Therapy Development for Leukemia

Creative Biolabs is a biotechnology company that is committed to offering a series of high-quality γδ T cell development services for global clients at a competitive price, involving anti-tumor γδ T cell discovery, culturing, isolation as well as preclinical validation trials. Our professional experts have a deep understanding of the role of γδ T cells in leukemia progression. We can provide optimal solutions for the development of γδ T cell based immunotherapy for leukemia.

γδ T Cell and Leukemia

Leukemia is a type of cancer that affects the body's blood-forming tissues, including the bone marrow and the lymphatic system. It is caused by a rise in the number of white blood cells in the body. National Cancer Institute estimated that about 61,780 people will be diagnosed as leukemia in 2019. Recently, some studies have reported that γδ T cells play an important role in killing leukemia. In the in vitro studies, γδ T cells showed a response to primary leukemic cells, characterized by proliferation, an increased proportion of Vδ1+ T cells, and cytotoxicity to the primary leukemia blasts. Increasing evidence has revealed that γδ T cells are capable of efficiently killing tumor and leukemia cells, thus offering a novel way for leukemia treatment.

Fig.1 Antitumour versus protumor roles of mouse γδ T cells. (Silva-Santos, 2015)

γδ T Cell Based Immunotherapy for Leukemia

Several studies have revealed γδ T cells are expected to as potent anti-tumor effector cells against leukemia due to their antitumor cytotoxicity. Human Vδ1 γδ T cells expanded from peripheral blood have shown their cytotoxicity to B-cell chronic lymphocytic leukemia (B-CLL)-derived cells. Especially, human Vδ1 T cells can recognize ULBP3 expressed on B-CLL and exert anti-tumor effect via ADCC. Besides, human Vγ9Vδ2 T cells have also been reported to specifically recognize and kill AML blasts. Overexpression of ULBP1 and ULBP4 on leukemia activated Vγ9Vδ2 T cell cytotoxicity to tumor cells. Human Vγ9Vδ2 T cells have been shown to kill CLL cells through the expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Moreover, CD16+Vγ9Vδ2 T cells have been reported to recognize monoclonal antibody coated lymphoma and CLL and exert anti-tumor effect via ADCC. These results suggest γδ T cell based immunotherapy may be a novel approach to leukemia treatment.

Fig.2 Appropriate stimulation allows an efficient Vγ9Vδ2 T cells anti-leukemic response. (Gertner-Dardenne, 2012)

What Can We Provide?

Creative Biolabs has focused on the research of γδ T cell immunotherapy for years. Owing to the robust anti-tumor activity of certain γδ T cell subpopulations, they are expected to become promising tools for the treatment of leukemia. Our excellent experts are confident in offering a variety of solutions for the development of γδ T cell. Our services include but not limited to:

• Discovery of anti-tumor γδ T cells
• Isolation and culture of anti-tumor γδ T cells
• γδ T cell modification
• Development of CAR γδ T cells
• Preclinical trials to validation safe and efficacy of γδ T cell immunotherapy

Features

• A seasoned expert team providing real-time technical support
• Advanced technologies ensuring reliable experiment data
• In-time data feedback to accelerate project progress
• Excellent after-sales service

If you are interested in our γδ T cell development services, please contact us for more details.

References

1. Silva-Santos, B.; et al. γδ T cells in cancer. Nature Reviews Immunology. 2015, 15:683-691.
2. Gertner-Dardenne, J.; et al. Immunotherapy of acute myeloid leukemia based on γδ T cells. Oncoimmunology. 2012, 1(9):1614-1616.